Angiogenesis is a multi-step process that culminates in vascular maturation whereby nascent vessels stabilize to become functional, and mural cells play an essential role in this process. Recent studies have shown that mural cells in tumors also promote and maintain vascular integrity, with wide-reaching clinical implications including the regulation of tumor growth, metastases, and drug delivery. Various regulatory signaling pathways have been hitherto implicated, but whether regulation of Fas-dependent apoptotic mechanisms is involved has not yet been fully investigated. We first compared endothelial FAS staining in human pancreatic ductal adenocarcinomas and colon carcinomas and show that the latter, characterized by lower mural cell coverage of tumor vasculature, demonstrated higher expression of FAS than the former. Next, in an in vitro coculture system of MS-1 and 10T1/2 cells as endothelial and mural cells respectively, we show that mural cells decreased endothelial Fas expression. Then, in an in vivo model in which C26 colon carcinoma cells were inoculated together with MS-1 cells alone or with the further addition of 10T1/2 cells, we demonstrate that mural cells prevented hemorrhage. Finally, knockdown of endothelial Fas sufficiently recapitulated the protection against hemorrhage seen with the addition of mural cells. These results together suggest that regulation of endothelial Fas signaling is involved in the promotion of vascular integrity by mural cells in tumors.
Angiogenesis is a multi-step process that culminates in vascular maturation whereby nascent vessels stabilize to become functional, and mural cells play an essential role in this process. Recent studies have shown that mural cells in tumors also promote and maintain vascular integrity, with wide-reaching clinical implications including the regulation of tumor growth, metastases, and drug delivery. Various regulatory signaling pathways have been hitherto implicated, but whether regulation of Fas-dependent apoptotic mechanisms is involved has not yet been fully investigated. We first compared endothelial FAS staining in human pancreatic ductal adenocarcinomas and colon carcinomas and show that the latter, characterized by lower mural cell coverage of tumor vasculature, demonstrated higher expression of FAS than the former. Next, in an in vitro coculture system of MS-1 and 10T1/2 cells as endothelial and mural cells respectively, we show that mural cells decreased endothelial Fas expression. Then, in an in vivo model in which C26 colon carcinoma cells were inoculated together with MS-1 cells alone or with the further addition of 10T1/2 cells, we demonstrate that mural cells prevented hemorrhage. Finally, knockdown of endothelial Fas sufficiently recapitulated the protection against hemorrhage seen with the addition of mural cells. These results together suggest that regulation of endothelial Fas signaling is involved in the promotion of vascular integrity by mural cells in tumors.
A berrant angiogenesis is a hallmark of cancer. (1, 2) Angiogenesis is a multi-step process culminating in vessel maturation in general, an indispensable step for nascent vessels to become functional. (3) Mural cells, which include pericytes and vascular smooth muscle cells, play a key role in vessel maturation via promotion of vascular integrity. (4) (5) (6) (7) (8) Knockout studies have highlighted the quintessentially important role of mural cells, as mural cell defective mice are often embryonic lethal due to extensive hemorrhage. (9) Recent studies have established that mural cells in tumors also participate in the promotion and maintenance of vascular integrity, with wide-ranging clinical implications including regulation of tumor growth, (10) metastases, (11, 12) and drug delivery. (13) Numerous reports to date have investigated and elucidated various pro-survival signaling pathways crucial to the regulation of vascular integrity. (7) However, whether anti-apoptotic mechanisms via regulation of endothelial Fas signaling, suggested to be important in angiogenic processes, (14) are involved has not yet been fully addressed. Fas, also known as CD95 or APO-1, is a death receptor which induces apoptosis via the extrinsic pathway. (15) Previous reports have described Fasmediated endothelial apoptosis in several physiological (16) (17) (18) (19) (20) and pathological (21) (22) (23) conditions, but whether mural cells also engage these mechanisms is unknown.
In the present study we show that human colon carcinomas, which are characterized by low mural cell coverage of vasculature, demonstrate higher FAS expression in endothelium compared to pancreatic ductal adenocarcinomas which are characterized by high mural cell coverage. Then, we show, both in vitro and in vivo, that mural cells decrease endothelial Fas expression, suggesting that endothelial cells are more resistant to apoptosis in the presence of mural cells. By establishing a novel tumor vessel model in which mural cell coverage of blood vessels can be experimentally manipulated, we demonstrate that blood vessels without mural cell coverage are more prone to hemorrhage, which can be rescued either by the presence of mural cells or knockdown of endothelial Fas expression.
Materials and Methods
Immunohistochemistry: human histopathology. The histological analysis of human pathological specimens in this study was performed with the approval of the Internal Review Board on Ethical Issues of Hokkaido University Graduate School of Medicine, Sapporo, Japan. The samples and the patients' information were obtained under a blanket written informed consent. The samples analyzed in this study were obtained from patients who underwent surgery in related hospitals in Hokkaido, whose final pathological diagnosis was made in Hokkaido University Graduate School of Medicine, Department of Cancer Pathology. Samples were embedded in paraffin, subjected to hematoxylin and eosin (HE) staining or immunohistochemistry (performed by Morphotechnology, Co. Ltd., Hokkaido, Japan) using primary antibodies against CD34 (Nichirei Bioscience Inc., Tokyo, Japan), smooth muscle actin (Dako Japan Co., Kyoto, Japan), and/or FAS (Cell Signaling Technology, Danvers, MA, USA), and analyzed with a Keyence BIOREVO BZ-9000 fluorescence microscope (Osaka, Japan). To quantify mural cell coverage and FAS positive vessels, vessels were manually traced and the length of vessels with mural cell coverage or FAS staining was divided by the total length of vessels using ImageJ software (NIH, Bethesda, MD, USA).
Cell culture. The Mile Sven 1 (MS-1) cell line, 10T1/2 cell line, and C26 cell line were obtained from American Type Culture Collection (Manassas, VA, USA), the Cancer Institute of the Japanese Foundation for Cancer Research (Tokyo, Japan), and National Cancer Center Research Institute (Tokyo, Japan), respectively. All cell lines were cultured in Dulbecco's modified Eagle medium (DMEM), high-glucose (Gibco/Life Technologies, Carlsbad, CA, USA) containing 10% fetal bovine serum (FBS). Lentiviral vector systems, a kind gift from Dr. Hiroyuki Miyoshi (RIKEN, Ibaraki, Japan), were used to express the enhanced green fluorescent protein (eGFP) gene and the DsRed gene in MS-1 cells and 10T1/2 cells, respectively. The sequence for DsRed was obtained from pDsRed-Express Vector (Takara Bio Inc., Shiga, Japan).
RNA isolation and quantitative reverse transcription-polymerase chain reaction (qRT-PCR). Total RNA was extracted from cells using the RNeasy Mini Kit (Qiagen, Venlo, Netherlands) or Sepasol-RNA I Super G (Nacalai Tesque, Kyoto, Japan). First-strand cDNAs were synthesized by PrimeScript 1st strand cDNA Synthesis Kit (Takara Bio Inc.) or ReverTra Ace -a-(TOYOBO, Osaka, Japan) with the respective random primers supplied by the manufacturer. qRT-PCR analyses were carried out using FastStart Universal SYBR Green Master (ROX) (Roche Applied Science, Upper Bavaria, Germany) or THUN-DERBIRD SYBR qPCR Mix (TOYOBO), and the StepOne Plus Real-Time PCR System (Applied Biosystems, Foster City, CA, USA). The expression of each gene was normalized by hypoxanthine phosphoribosyl transferase 1 (Hprt1) gene expression. The primer sequences used in this study were as follows: GTTCTTTGCTGACCTGCTGGAT and CTTTTA TGTCCCCCGTTGACTG for murine Hprt1, GTCCGCCCT GAGCAAAGA and TCCAGCAGGACCATGTGATC for eGFP, AAGTCCATCTACATGGCCAAGAA and TCCAG CTTGGAGTCCACGTAGT for DsRed, and TTCTCCT GGCTGTGAACACTGT and CACGGCTCAAGGGTTCCAT for murine Fas.
In vitro coculture system. MS-1 cells stably expressing eGFP and 10T1/2 cells stably expressing DsRed were seeded separately or together in a 1 Induction and detection of apoptosis. MS-1 cells and 10T1/2 cells were seeded in l-Slide VI 0.4 (ibiTreat) from Ibidi (Martinsried, Germany). After 2 days of culture in DMEM with 10% FBS, the medium was replaced with fresh DMEM containing 1% FBS, and cells at 75% confluence were incubated for 24 h to induce apoptosis using 20 lg/mL of antimouse Fas monoclonal antibody (clone Jo2) or isotype control (BD Biosciences Pharmingen, San Diego, CA, USA). For quantification of cleaved Caspase-3, the incubated cells were fixed for 3 min with Mildform 10N (Wako, Osaka, Japan) after 24 h of apoptosis induction. Cells were immunostained by the same procedure as for immunohistochemistry described below, using rat anti-platelet endothelial cell adhesion molecule-1 (PECAM-1) monoclonal antibody (clone MEC 13.3; 1:150; BD Biosciences Pharmingen) and rabbit anti-cleaved Caspase-3 (Asp175) polyclonal antibody (1:400; Cell Signaling Technology) and 4 0 ,6-diamidino-2-phenylindole (DAPI) (1 lg/ mL; Invitrogen/Molecular Probes, Eugene, OR, USA), and were observed with a LSM510 Meta confocal microscope (Carl Zeiss, Oberkochen, Germany) and/or BIOREVO BZ-9000. The apoptosis index was calculated by counting the number of cleaved Caspase-3 positive endothelial cells for each condition and then normalizing by cell number.
siRNA oligonucleotides transfection. The 23 nucleotide siRNA duplexes were designed using Enhanced siDirect (RNAi, Inc., Tokyo, Japan). The specific target sequence for mouse Fas siRNA, 5 0 -CAGAAATCGCCTATGGTTGTTGA-3 0 , and the negative control siRNA were purchased from RNAi, Inc. MS-1 cells were transfected with siRNA oligonucleotides using Lipofectamine RNAiMAX (Life Technologies) reagent according to manufacturer's instructions. The medium was replaced 24 h after transfection.
Animals. BALB/c-nu/nu male mice at 5 weeks of age were bought from Charles River Laboratories Japan (Kanagawa, Japan) or Japan SLC (Shizuoka, Japan). All animal experiments were approved and carried out in accordance with the policies of the Animal Ethics Committee at the University of Tokyo and with the Policy on the Care and Use of the Laboratory Animals, Okayama University.
In vivo model for angiogenesis. BALB/c-nu/nu mice at 5 weeks of age were inoculated subcutaneously in the left flank with C26 murine colon carcinoma cells simultaneously with MS-1 murine endothelial cells with or without the further addition of 10T1/2 murine mural precursor cells. (24, 25) 10T1/2 cells with DsRed expression (M for mural cells; 1.5-2 9 10
Fas knocked down (E-FasKD; 1.5-2 9 10 6 cells), and C26 cancer cells (5 9 10 5 cells) were suspended in PBS and mixed with an equal volume of Matrigel (BD Biosciences) for a total of 200 lL for subcutaneous inoculation. For the sake of brevity, we named the condition in which MS-1 cells were inoculated together with C26 cells as the E (for "endothelial cells only") condition and the condition with the further addition of 10T1/2 cells as E+M (for "endothelial cells + mural cells") condition. Macroscopic photographs of xenograft tumors were obtained on day 4, and the presence and degree of hemorrhage was scored. The degree of hemorrhage was scored as follows: "moderate" if tumors appeared purplish and "severe" if overt subcutaneous hemorrhage emanating from the xenograft was observed. Samples were harvested on day 3 for analysis of endothelial Fas expression and apoptosis, and day 7-10 for analyzing hemorrhage. Samples were cut in half upon harvesting. One half was fixed overnight in Mildform 10N, embedded in paraffin, subjected to HE staining or immunohistochemistry (performed by Morphotechnology, Co. Ltd.), and analyzed with BIOREVO BZ-9000. The other half was embedded in O.C.T. Compound (Sakura Finetek/Tissue-Tek, Torrance, CA, USA) and frozen in dry-iced hexane for fluorescent immunostaining, either immediately when MS-1 cells and 10T1/2 cells were not labeled, or after the following procedure when eGFPlabeled MS-1 cells or DsRed-labeled 10T1/2 cells were used: samples were fixed for 30 min at room temperature with Mildform 10N and washed overnight at 4°C thrice, in PBS with 10%, 15%, and 20% sucrose sequentially.
Immunohistochemistry: animal model. Frozen samples were sectioned at a thickness of either 5 or 10 lm with a cryostat, fixed with Mildform 10N for 3 min, blocked with Blocking One (Nacalai Tesque), and were incubated for 2 h with one or more primary antibodies listed below: rat anti-PECAM-1 monoclonal antibody (1:150), mouse anti-actin, alpha-smooth muscle (a-SMA)-Cy3 monoclonal antibody (clone 1A4; 1:100; SigmaAldrich), rabbit anti-NG2 chondroitin sulfate proteoglycan polyclonal antibody (1:200; Chemicon/Merck Millipore, Darmstadt, Germany), rabbit anti-cleaved Caspase-3 (Asp175) polyclonal antibody (1:600), and rabbit anti-CD95 (Fas) polyclonal antibody (1:50; Abcam, Cambridge, UK). Subsequently, specimens were incubated for 1.5 h with the appropriate secondary antibodies labeled with Alexa Fluor 488, Alexa Fluor 594, or Alexa Fluor 647 (1:200; Invitrogen/Molecular Probes). Cell nuclei were then counterstained with DAPI (1 lg/mL) for 5 min and mounted with Fluorescent Mounting Medium (Dako, Glostrup, Denmark). Terminal deoxynucleotidyl Transferase (TdT)-mediated dUTP nick end labeling (TUNEL) staining, together with staining for eGFP using anti-GFP polyclonal antibody (Medical & Biological Laboratories, Nagoya, Japan) was performed by Morphotechnology, Inc. Stained samples were observed with LSM510 Meta and/or BIOREVO BZ-9000.
Image quantification and statistical analysis. Collected images were processed or quantified by ImageJ software, BZ-II analyzer (Keyence), LSM Image Browser (Carl Zeiss), and/or Photoshop (Adobe systems, Inc., San Jose, CA, USA). To quantify the proportion of 10T1/2 cells which become NG2 positive and also the proportion of NG2 positive cells derived from 10T1/2 cells, area doubly positive for NG2 and DsRed were divided by area positive for DsRed or NG2, respectively. For quantification of cleaved Capsase-3 positive vessels, the number of cleaved Caspase-3 positive cells were counted and normalized by PECAM-1 positive area in 3D projected images. To quantify TUNEL positive vessels, TUNEL positive area was divided by PECAM1 positive area. For quantification of the degree of hemorrhage, we divided the sum of the lengths of hemorrhagic vessels by total vessel length using the HE stained samples. Hemorrhagic vessel was defined as vessel having extravasated red blood cells (RBCs) within 25 lm outside the vessel wall. Vessel lengths were measured by manual tracing using Photoshop followed by quantification using ImageJ software. Statistical analysis was performed with GraphPad Prism (GraphPad Software, La Jolla, CA, USA). Data were analyzed by Student's t-test or analysis of variance (ANOVA) followed by Tukey's multiple comparison test.
Results
We have previously investigated mural cell coverage of tumor vasculature in various human tumors (26) and noted significantly different levels of coverage depending on tumor type. Pancreatic ductal adenocarcinomas, for example, show significantly greater mural cell coverage of tumor vessels than colon carcinomas. Building on this observation, we first performed immunohistochemical analysis of human pancreatic ductal adenocarcinoma and colon carcinoma tissue samples to assess whether degree of mural cell coverage may correlate with endothelial Fas expression. We first confirmed, consistent with our previous analyses, that colon carcinomas were characterized with vasculature (visualized by CD34) with a lower level of coverage by a-smooth muscle actin (a-SMA) positive mural cells than pancreatic ductal adenocarcinomas (Fig. 1a-d) . Comparison of Fas expression between these tumors revealed that many Fas-positive blood vessels were present in colon carcinomas but not in pancreatic ductal adenocarcinoma (Fig. 1e-h ). Quantification of a-SMA positive mural cell coverage (Fig. 1i) and Fas positivity (Fig. 1j ) of CD34 positive tumor neovessels confirmed the above observations.
We therefore asked whether a causative relationship exists between mural cell coverage and Fas expression of tumor vessels. To this end, we first cocultured MS-1 endothelial cells fluorescently labeled by eGFP and 10T1/2 mesenchymal stem cells labeled by DsRed as mural cell progenitors. After 2 days of coculture in vitro (Fig. 2a) , MS-1 cells and 10T1/2 cells were separated by FACS and subjected to qRT-PCR analysis. By quantifying eGFP and DsRed mRNA expression, we confirmed successful segregation of the two cell types (Fig. 2b) . We then quantified Fas mRNA expression in MS-1 cells and found that it was significantly decreased in the presence of 10T1/2 cells (Fig. 2c) . We then wondered whether the decrease in Fas mRNA expression is due to a general downregulation of Fas in MS-1 cells cocultured with 10T1/2 cells or alternatively due to down-regulation within a select subpopulation of MS-1 cells. We thus performed flow cytometry and discovered that Fas expression was mildly decreased in the whole cocultured MS-1 population compared to monocultured MS-1 cells (Fig. S1 ). We next sought to address the functional significance of the down-regulation of Fas expression in MS-1 cells by treating both culture conditions with Jo2, a Fas agonist monoclonal antibody. Jo2 significantly induced the apoptosis of monocultured MS-1 cells, but the effect was largely abrogated in MS-1 cells cocultured with 10T1/2 cells (Fig. 2d) suggesting that the down-regulation of MS-1 Fas expression conferred enhanced resistance to Fas-mediated apoptosis and was thus indeed functionally important. The above data suggest that the presence of mural cells result in decreased endothelial Fas expression and lessened endothelial susceptibility to Fas-mediated apoptosis.
We next asked whether a similar mechanism may be at play in tumors in vivo. To this end, we established a novel xenograft model in which the presence of mural cell coverage can be easily manipulated by inoculating C26 murine colon carcinoma cells with MS-1 cells (E, for endothelial cell) only or MS-1 cells together with 10T1/2 cells (M, for mural cell), to test whether endothelial-mural cell interactions result in the decrease of endothelial Fas expression. Implantation of C26 tumor cells with MS-1 cells only (E condition) results in a tumor with neovasculature hardly covered by mural cells, but the 10T1/2 cells added in the E+M condition successfully associated with the induced neovasculature and resulted in a conspicuous increase in NG2-positive mural cell coverage of neovessels (Fig. 3a,b) . By quantifying DsRed and NG2 double (Fig. 3c,d ). Taken together, these results suggest that the addition of 10T1/2 cells in the E+M condition indeed results in increased mural cell coverage both directly by differentiation of 10T1/2 cells into NG2 positive mural cells and indirectly via a 10T1/2 cell non-autonomous mechanism. Notably, fluorescent immunostaining of Fas revealed a significant decrease of Fas expression in the endothelium of E+M condition xenografts compared to that of E condition (Fig. 3e,f) . Furthermore, the degree of endothelial apoptosis, defined as cleaved Caspase-3/PECAM-1 doublepositive cells, (27, 28) was significantly decreased in the E+M condition than in the E condition (Fig. 3g,h) . We additionally performed TUNEL staining to compare the number of apoptotic endothelial cells, and found that there were significantly more TUNEL positive MS-1 cells in the E condition xenografts than in the E+M condition xenografts (Fig. S2a,b) .
Taken together, these findings, which were very much in line with the results obtained from the in vitro coculture system, together suggest that the presence of mural cells also decreased endothelial Fas expression and conferred strengthened resistance to Fas-mediated apoptosis in vivo even within tumors.
Finally, we assessed the effect of the presence of mural cells and the resultant down-regulation of endothelial Fas expression on vascular integrity by quantifying hemorrhage, an indicator of immature vasculature, in the xenografts (Fig. 4a) . E+M condition xenografts showed a significant reduction of hemorrhage compared to E condition xenografts (Fig. 4b) , in line with a previous report demonstrating the importance of mural cells in vascular integrity. (4) We further exploited this model to definitively establish the functional significance of mural cellinduced endothelial Fas down-regulation by siRNA-mediated knockdown of Fas expression in MS-1 cells (E-FasKD, Fig. 4c ). Indeed, we discovered that E-FasKD condition xenografts showed a significant reduction in hemorrhage compared to E condition xenografts, to a level much comparable to E+M condition xenografts (Fig. 4a,b) . These findings were in line with macroscopic observations which revealed the occurrence of severe hemorrhage in E condition xenografts, while E+M and E-FasKD condition xenografts demonstrated hemorrhage of diminished severity (Fig. S3) . Altogether, these results suggest that the presence of mural cells decrease the expression of endothelial Fas and that this alone sufficiently recapitulates the promotion of vascular integrity by mural cells at least as determined by extent of hemorrhage.
Discussion
Fas-mediated apoptosis in endothelium has been observed in several physiological and pathological conditions, (16) (17) (18) (19) (20) (21) (22) (23) but its role and regulation in the promotion and maintenance of vascular integrity was unclear. Mural cells have been reported to be an essential player in the regulation of vessel integrity, (4) but little was hitherto known about how death signals or death receptors in endothelium are affected by the presence of mural cells in tumors.
The present study first shows correlation between mural cell coverage of tumor vasculature and endothelial Fas expression in human pancreatic and colon carcinoma tissue samples. However, we have interestingly noticed that not all vessels without mural cell coverage were positive for Fas. Alternative mechanisms governing endothelial Fas expression (29) independent of mural cell coverage may be one reason for this discrepancy. We further surmised that histological analysis of human surgical specimens, which allows observation of only a singular given point in time for a given patient, might not be optimally suited for the visualization and dissection of the highly dynamic and complex process of vascular maturation.
We therefore demonstrate both in vitro and in vivo using a novel coculture system, which allows the manipulation of mural cell coverage against a uniform background that the presence of mural cells results in endothelial resistance to apoptosis at least partly via a decrease in endothelial Fas expression. We further show that forced down-regulation of endothelial Fas functioned to attenuate the extent of hemorrhage in vivo in a C26 tumor xenograft model even in the absence of mural cells, thus providing preliminary evidence that mural cell-induced decrease of endothelial Fas is indeed involved in the regulation of vascular integrity. We have adopted hemorrhage as a marker of vascular integrity since previous reports establishing the essential role of mural cells have demonstrated that mural cell-loss leads to embryonic lethality and is characterized by extensive hemorrhage. (9, 30) Currently, how down-regulation of endothelial Fas leads to decreased hemorrhage remains unclear. Taking into account the well-known role of Fas in the extrinsic pathway of apoptosis, we surmise that enhanced resistance of endothelial cells to apoptosis results in increased endothelial survival, thus enabling the formation of functional endothelial-endothelial junctions from an earlier stage. Recent reports, however, have also described apoptosis-independent roles of Fas signaling such as regulation of calcium influx in lymphocytes and dendritic branching in neurons. (31, 32) Further research is thus warranted to elucidate how mural cells downregulate endothelial Fas expression and how, in turn, decreased Fas expression in endothelium results in enhanced barrier integrity in tumors. A related question of importance is the nature of the Fas ligand expressing cells, which would presumably be necessary for Fas-mediated regulation of endothelial cell death. Preliminary immunohistochemical analyses revealed that Fas ligand expression was fairly ubiquitously seen throughout the xenograft, including in endothelial cells themselves (data not shown). Though we have not yet clearly delineated the exact nature of the Fas ligand expressing cells and further the specific contribution of each cell population in death signaling mediated through endothelial Fas, it at least seems reasonable to conclude that regulation of Fas expression in endothelial cells is of great importance in such an environment.
The findings presented in this work were obtained via the establishment of a new in vivo model. Previous works have analyzed the function of mural cells by, for example, respectively implanting different cancer cells with varying capacities to induce vasculature with mural cell coverage, (33) genetic ablation of specific mural cell markers, (4) or pharmacologic disruption of endothelial-mural cell association. (34) Though these works have shed light on important aspects of endothelial-mural cell interaction, the difference between vessels with or without mural cells could not simply be attributed to the function of mural cells. We have addressed this difficulty by generating a new additive xenograft model, where C26 tumor cells, MS-1 endothelial cells, and 10T1/2 mural cell progenitors were xenografted together into nude mice. Two main limitations of our model, however, should especially be noted. First, the induced vasculature of the xenografts does not solely consist of the co-inoculated MS-1 cells, and there is a significant contribution of host endothelial cells. Thus for example in the E-FasKD condition, Fas knockdown is not uniformly accomplished in endothelial cells within the xenografts. Even then, it seems that the extraneously injected MS-1 cells with siRNA-mediated down-regulation of Fas expression were sufficient to prevent hemorrhage. Secondly, we have only tested a particular tumor cell/endothelial cell/mural cell combination in this study. Further studies comparing various combinations may be useful in elucidating both conserved and context-specific mechanisms governing the regulation of vascular integrity.
Two peaks in PECAM1 fluorescence were observed in the coculture condition: the major peak which coincided with the peak seen in monocul- 
